• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis . Binding and avidity signatures of polyclonal sera from individuals with different exposure histories to SARS-CoV-2 infection, vaccin

tetano

Editor, Senior Moderator
J Infect Dis


. 2023 Apr 27;jiad116.
doi: 10.1093/infdis/jiad116. Online ahead of print. Binding and avidity signatures of polyclonal sera from individuals with different exposure histories to SARS-CoV-2 infection, vaccination, and Omicron breakthrough infections

Gagandeep Singh[SUP] 1 2 [/SUP], Anass Abbad[SUP] 1 2 [/SUP], Johnstone Tcheou[SUP] 1 2 [/SUP], Demodara Rao Mendu[SUP] 3 [/SUP], Adolfo Firpo-Betancourt[SUP] 3 [/SUP], Charles Gleason[SUP] 1 2 [/SUP], Komal Srivastava[SUP] 1 2 [/SUP], Carlos Cordon Cardo[SUP] 3 [/SUP], Viviana Simon[SUP] 1 2 3 4 5 [/SUP], Florian Krammer[SUP] 1 2 3 [/SUP], Juan Manuel Carreño[SUP] 1 2 [/SUP]



Affiliations
Abstract

Background: The number of exposures to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to vaccination antigens impact the magnitude and avidity of the polyclonal response.
Methods: We studied binding and avidity of different antibody isotypes to the spike, the receptor binding domain (RBD), and the nucleoprotein (NP) of wild type (WT) and BA.1 SARS-CoV-2 in convalescent, mRNA vaccinated, mRNA boosted, hybrid immune individuals, and in individuals with breakthrough cases during the peak of the BA.1 wave.
Results: We found an increase in spike binding antibodies and antibody avidity with increasing number of exposures to infection and/or vaccination. Nucleoprotein antibodies were detectible in convalescent individuals and a proportion of breakthrough cases, but displayed low avidity. Omicron breakthrough infections elicited high levels of cross-reactive antibodies between WT and BA.1 antigens in vaccinated individuals without prior infection directed against the spike and receptor binding domain (RBDs). The magnitude of the antibody response and avidity correlated with neutralizing activity against WT virus.
Conclusions: The magnitude and quality of the antibody response increased with the number of antigen exposures, including breakthrough infections. However, cross-reactivity of the antibody response after BA.1 breakthroughs, was impacted by the number of prior antigenic exposures.

Keywords: Omicron; SARS-CoV-2; antibodies; avidity; neutralization.

 
Back
Top Bottom